Peter van der Velden is currently the managing general partner of Lumira Capital, Canada’s largest dedicated life sciences venture capital investor. He has previous experience in banking, venture capital, and private equity investing.

Ken d’Entremont is the founder, president, and CEO of Medexus Inc. Previously, he was the general manager and vice president of business development at Sanofi, where he led the in-licensing initiatives for Sanofi Canada. Mr. d’Entremont holds a Bachelor of Science in Chemistry from McMaster University.

Michael Mueller is currently chairman of Laurentian Bank of Canada. He was the former chairman of the Public Sector Pension Investment Board and former chair of its compensation committee. He has held senior positions at TD Bank Financial Group, including senior vice president and country head of its USA division, and was a former director of MDS Capital Corporation, and other notable funds and ventures.

Benoit Gravel has 30 years of experience in the pharmaceutical industry from his work at Rhône-Poulenc, Aventis and Sanofi. Mr. Gravel has held several commercial executive positions in Canada, including vice-president diabetes & specialized care patient centered unit at Sanofi. He began his career as an economist in the energy and transportation industries.

Stephen Nelson served as senior vice president, portfolio manager, and investment advisor with TD Wealth Private Investment Advice. Mr. Nelson currently manages over $2 billion in investment assets and has been a member of TD Waterhouse’s President Club for the past 16 consecutive years. He has also served as a director for a number of private companies.

Ms. Gulfo currently serves as Chief of Commercial Development at Roivant Sciences Ltd., Previously, Ms. Gulfo served as EVP & Head of Global Commercial Development as well as Chief Strategy Officer of Mylan N.V. (NASDAQ: MYL). Prior to joining Mylan, Ms. Gulfo spent a total of 14 years at Pfizer, Inc. and predecessor companies. Among her senior roles at Pfizer, Ms. Gulfo served as President and General Manager of Pfizer’s U.S. Primary Care Business, a $12+ billion unit comprising over 5,000 employees across multiple therapeutic areas.